EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1 / 3 mRNA Expression

Cora N Sternberg iD, Daniel P Petrylak iD, Joaquim Bellmunt iD, Hiroyuki Nishiyama, Andrea Necchi iD, Howard Gurney iD, Jae-Lyun Lee iD, Michiel S van der Heijden iD, Eli Rosenbaum, Nicolas Penel iD, See-Tong Pang, Jian-Ri Li iD und 11 weitere

Journal of Clinical Oncology · 20.01.2023 · 41 (3) · 629-639

DOI: 10.1200/jco.21.02303 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2023. Verfasst von Cora N Sternberg und 22 weiteren Autor:innen. Beteiligte Einrichtung: Englander Institute for Precision Medicine, Weill Cornell Medicine, Sandra and Edward Meyer Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with advanced urothelial carcinoma (UC) with FGFR1-3 mRNA overexpression. We assessed rogaratinib efficacy and safety versus chemotherapy in patients with FGFR mRNA-positive advanced/metastatic UC previously treated with platinum chemotherapy. METHODS FORT-1 (ClinicalTrials.gov identifier: NCT03410693 ) was a phase II/III, randomized, open-label trial. Patients with FGFR1/ 3 mRNA-positive locally advanced or metastatic UC with ≥ 1 prior platinum-containing regimen were randomly assigned (1:1) to rogaratinib (800 mg orally twice daily, 3-week cycles; n = 87) or chemotherapy (docetaxel 75 mg/m 2 , paclitaxel 175 mg/m 2 , or vinflunine 320 mg/m 2 intravenously once every 3 weeks; n = 88). The primary end point was overall survival, with objective response rate (ORR) analysis planned following phase II accrual. Because of comparable efficacy between treatments, enrollment was stopped before progression to phase III; a full interim analysis of phase II was completed. RESULTS ORRs were 20.7% (rogaratinib, 18/87; 95% CI, 12.7 to 30.7) and 19.3% (chemotherapy, 17/88; 95% CI, 11.7 to 29.1). Median overall survival was 8.3 months (95% CI, 6.5 to not estimable) and 9.8 months (95% CI, 6.8 to not estimable; hazard ratio, 1.11; 95% CI, 0.71 to 1.72; P = .67). Grade 3/4 events occurred in 37 (43.0%)/4 (4.7%) patients and 32 (39.0%)/15 (18.3%), respectively. No rogaratinib-related deaths occurred. Exploratory analysis of patients with FGFR3 DNA alterations showed ORRs of 52.4% (11/21; 95% CI, 29.8 to 74.3) for rogaratinib and 26.7% (4/15; 95% CI, 7.8 to 55.1) for chemotherapy. CONCLUSION To our knowledge, these are the first data to compare FGFR-directed therapy with chemotherapy in patients with FGFR-altered UC, showing comparable efficacy and manageable safety. Exploratory testing suggested FGFR3 DNA alterations in association with FGFR1/ 3 mRNA overexpression may be better predictors of rogaratinib response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Transitional CellUrinary Bladder NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsDNAPlatinumReceptor, Fibroblast Growth Factor, Type 1RNA, MessengerPiperazinesPyrrolesThiophenes

Substanzen

Antineoplastic AgentsDNAPlatinumReceptor, Fibroblast Growth Factor, Type 1RNA, MessengerFGFR1 protein, humanRogaratinibPiperazinesPyrrolesThiophenes

Autor:innen und Institutionen

  • Englander Institute for Precision Medicine, Weill Cornell Medicine, Sandra and Edward Meyer Cancer Center, New York, NY.
  • Yale Cancer Center, New Haven, CT.
  • Beth Israel Deaconess Medical Center and PSMAR-IMIM Lab, Boston, MA.
  • Harvard Medical School, Boston, MA.
  • Department of Urology, University of Tsukuba, Tsukuba, Japan.
  • Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy.

ORCID-Profile: Cora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, Andrea Necchi, Howard Gurney, Jae-Lyun Lee, Michiel S van der Heijden, Nicolas Penel, Jian-Ri Li, Xavier García Del Muro, Florence Joly, Tatiane Cristine Ishida, David I Quinn

Förderung

  • NCATS NIH HHS

Zitieren

APA

Sternberg, C. N., Petrylak, D. P., Bellmunt, J., Nishiyama, H., Necchi, A., Gurney, H., Lee, J. L., van der Heijden, M. S., Rosenbaum, E., Penel, N., Pang, S. T., Li, J. R., García Del Muro, X., Joly, F., Pápai, Z., Bao, W., Ellinghaus, P., Lu, C., Sierecki, M., …, & Quinn, D. I. (2023). FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1 / 3 mRNA Expression. Journal of Clinical Oncology, 41(3), 629-639. https://doi.org/10.1200/jco.21.02303

Vancouver

Sternberg CN, Petrylak DP, Bellmunt J, Nishiyama H, Necchi A, Gurney H, et al. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1 / 3 mRNA Expression. Journal of Clinical Oncology. 2023;41(3):629-639. doi:10.1200/jco.21.02303

BibTeX
@article{Sternberg2023,
  author = {Sternberg, Cora N and Petrylak, Daniel P and Bellmunt, Joaquim and Nishiyama, Hiroyuki and Necchi, Andrea and Gurney, Howard and Lee, Jae-Lyun and van der Heijden, Michiel S and Rosenbaum, Eli and Penel, Nicolas and Pang, See-Tong and Li, Jian-Ri and García Del Muro, Xavier and Joly, Florence and Pápai, Zsuzsanna and Bao, Weichao and Ellinghaus, Peter and Lu, Chengxing and Sierecki, Mitchell and Coppieters, Sabine and Nakajima, Keiko and Ishida, Tatiane Cristine and Quinn, David I},
  title = {FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1 / 3 mRNA Expression},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {3},
  pages = {629--639},
  doi = {10.1200/jco.21.02303}
}
Kostenlos starten →